StreetInsider.com News Articles

Genmab stock surges 9% following positive phase 3 ovarian cancer trial results

Fri, 23 Oct 2026 12:20:41 -0400

Investing.com -- Shares of Genmab A/S (NASDAQ: GMAB) rallied 9% on Friday following the announcement of positive top-line results from its Phase 3 RAINFOL-02 trial evaluating rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. Meanwhile, shares of Corcept Therapeutics (NASDAQ: CORT)—which recently gained approval for its own rival platinum-resistant ovarian cancer treatment, Lifyorli (relacorilant)—fell 11% in contrasting sector movement.

The pivotal study met both its primary endpoint of progression-free survival (PFS) and key secondary endpoint of overall survival (OS), delivering statistically significant and clinically meaningful improvements over investigator’s choice chemotherapy.

In the intent-to-treat population

Genmab stock surges 9% following positive phase 3 ovarian cancer trial results

Fri, 23 Oct 2026 12:20:41 -0400

In the intent-to-treat population

Genmab stock surges 9% following positive phase 3 ovarian cancer trial results

Fri, 23 Oct 2026 12:20:41 -0400

In the intent-to-treat population

Genmab stock surges 9% following positive phase 3 ovarian cancer trial results

Fri, 23 Oct 2026 12:20:41 -0400

In the intent-to-treat population

2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes

Tue, 20 Oct 2026 16:00:00 -0400

Joint recommendation cites Corcept’s CATALYST study on the prevalence and treatment of hypercortisolism in patients whose blood sugar remains high despite use of multiple glucose-lowering medications

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published their consensus report on the Management of Type 2 Diabetes, 2026, which recommends that clinicians

2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes

Tue, 20 Oct 2026 16:00:00 -0400

Corcept Therapeutics (CORT) spreader of 2500 contracts of January 120 and 160 calls

Tue, 20 Oct 2026 14:32:14 -0400

Corcept Therapeutics (NASDAQ: CORT) 30-day option implied volatility is at 65; compared to its 52-week range of 40 to 144 with the focus on a spreader of 2500 contracts of January 120 and 160 calls.

Form 4 CORCEPT THERAPEUTICS For: Oct 15 Filed by: WILSON JAMES N

Fri, 16 Oct 2026 18:25:00 -0400

si-local-file:///var/storage/secattach/20261016/27198905.html

Form 4 CORCEPT THERAPEUTICS For: Oct 02 Filed by: Vieira Roberto Wandenkolk

Mon, 05 Oct 2026 19:59:00 -0400

si-local-file:///var/storage/secattach/20261005/27150456.html

Form 4 CORCEPT THERAPEUTICS For: Oct 01 Filed by: Lyon Joseph Douglas

Mon, 05 Oct 2026 19:54:00 -0400

si-local-file:///var/storage/secattach/20261005/27150451.html

Form 4 CORCEPT THERAPEUTICS For: Oct 01 Filed by: Maduck Sean

Mon, 05 Oct 2026 19:49:00 -0400

si-local-file:///var/storage/secattach/20261005/27150444.html

Form 4 CORCEPT THERAPEUTICS For: Oct 01 Filed by: Gunn Justin Frederick

Mon, 05 Oct 2026 19:45:00 -0400

si-local-file:///var/storage/secattach/20261005/27150436.html

Form 3 CORCEPT THERAPEUTICS For: Oct 01 Filed by: Gunn Justin Frederick

Mon, 05 Oct 2026 19:18:00 -0400

si-local-file:///var/storage/secattach/20261005/27150409.html

Form 144 CORCEPT THERAPEUTICS Filed by: Lyon Joseph Douglas

Thu, 01 Oct 2026 11:09:00 -0400

si-local-file:///var/storage/secattach/20261001/27133734.html

Form 4 CORCEPT THERAPEUTICS For: Sep 24 Filed by: Robb Gary Charles

Mon, 28 Sep 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260928/27114947.html

Form 8-K CORCEPT THERAPEUTICS For: Sep 22

Wed, 23 Sep 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260923/27093665.html

Corcept names Justin Gunn president of endocrinology division

Wed, 23 Sep 2026 08:04:40 -0400

Corcept Therapeutics (NASDAQ: CORT) announced that Sean Maduck, president of its Endocrinology division, will retire, with Justin Gunn set to succeed him starting Oct. 1.

Gunn will join the company's Executive Team and report to Chief Executive Officer Joseph K. Belanoff, M.D. Maduck will remain with the company as a senior commercial advisor to assist with the transition.

Gunn joined Corcept in July 2024 as Vice President of Sales and Commercial Learning for its Oncology division, where he built a field sales and training organization to support the launch of Lifyorli, the company's treatment for platinum-resistant ovarian cancer. Before joining Corcept, Gunn

Corcept Announces Planned Leadership Transition

Wed, 23 Sep 2026 08:00:00 -0400

Sean Maduck to Retire; Justin Gunn Appointed President, Endocrinology

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the retirement of Sean Maduck, President of the company’s Endocrinology division. Justin Gunn will succeed Mr. Maduck and will fully assume his new responsibilities starting October 1. Mr. Gunn will join the company’s Executive Team, and will report to Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer. To enable

Corcept Announces Planned Leadership Transition

Wed, 23 Sep 2026 08:00:00 -0400

Sean Maduck to Retire; Justin Gunn Appointed President, Endocrinology

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the retirement of Sean Maduck, President of the company’s Endocrinology division. Justin Gunn will succeed Mr. Maduck and will fully assume his new responsibilities starting October 1. Mr. Gunn will join the company’s Executive Team, and will report to Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer. To enable

Form 4 CORCEPT THERAPEUTICS For: Sep 16 Filed by: Vieira Roberto Wandenkolk

Fri, 18 Sep 2026 19:54:00 -0400

si-local-file:///var/storage/secattach/20260918/27081542.html

Form 4 CORCEPT THERAPEUTICS For: Sep 17 Filed by: Robb Gary Charles

Fri, 18 Sep 2026 19:48:00 -0400

si-local-file:///var/storage/secattach/20260918/27081536.html

EU panel recommends approval of Corcept's relacorilant for ovarian cancer

Fri, 18 Sep 2026 08:00:25 -0400

Corcept Therapeutics (NASDAQ: CORT) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending that the European Commission approve relacorilant, sold under the trade name Lifyorli, in combination with the chemotherapy drug nab-paclitaxel, for the treatment of platinum-resistant ovarian cancer.

The CHMP's recommendation is based on data from Corcept's Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel showed improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of the combination was consistent with that of nab-paclitaxel alone.

The

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

Fri, 18 Sep 2026 08:00:00 -0400

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer.

The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

Fri, 18 Sep 2026 08:00:00 -0400

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer.

The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA

Form 4 CORCEPT THERAPEUTICS For: Sep 15 Filed by: WILSON JAMES N

Wed, 16 Sep 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260916/27070666.html